sermorelin vs tesamorelin: Frequently asked questions

Use sermorelin at 1 mcg/kg subcutaneously before sleep and measure serum GH at 30, 60, and 120 minutes post-injection. Sermorelin's rapid onset and short half-life make it the standard comparator for acute GH secretory capacity. It produces sharp, measurable peaks that reflect pituitary responsiveness. Tesamorelin's sustained release profile blunts peak amplitude, making it less suitable for diagnostic protocols where you need to distinguish normal vs blunted GH response.

Tesamorelin is the only peptide with demonstrated, reproducible visceral fat loss in controlled trials. Select it as the primary intervention and dose at 2 mg daily for a minimum 12-week protocol. Sermorelin will not produce meaningful VAT reduction even at higher doses because it lacks the tissue-specific lipolytic mechanism tesamorelin's hexenoic acid modification confers. Measuring visceral adipose volume by CT or MRI at baseline and endpoint is essential. Waist circumference and BMI are insufficient proxies.

Sermorelin offers better cost-per-dose when visceral fat is not the primary outcome. A 5 mg vial at $250 provides 25–30 doses at 1.5 mcg/kg for a 70 kg subject, whereas tesamorelin's fixed 2 mg dose costs $280–$450 per vial with no weight-based adjustment. For protocols running 16–24 weeks evaluating lean mass or bone mineral density, sermorelin's lower per-dose cost compounds significantly. Budget accordingly during grant planning.

Sermorelin offers better cost-per-dose value. At $120–180 per 5mg vial versus $240–350 per 2mg vial for tesamorelin, sermorelin provides 2–3× more doses per dollar. For long-term studies requiring months of daily administration, this difference compounds significantly. If your research question doesn't specifically require tesamorelin's visceral fat mechanism, sermorelin is the economically rational choice without sacrificing research quality.

The tesamorelin + ipamorelin blend is mechanistically superior. Ipamorelin improves insulin sensitivity through ghrelin receptor pathways (documented 18% reduction in fasting insulin and 22% improvement in HOMA-IR), while tesamorelin drives lipolysis in visceral adipose tissue where insulin resistance originates. Sermorelin's indirect metabolic effects via GH normalization aren't sufficient when glucose handling and abdominal fat are primary outcomes. Protocol duration should be at least 16 weeks to capture meaningful metabolic changes. Shorter trials may miss the full effect.

Sermorelin is the cost-effective choice, but expect more modest GH elevation and no direct fat loss effects. A 12-week sermorelin protocol costs $240–$360 versus $480–$720 for the blend. If you must work within budget and still need metabolic outcomes, consider extending sermorelin duration to 24 weeks rather than switching to combination therapy for 12 weeks. Cumulative GH normalization over time can produce indirect metabolic improvements, though not at the magnitude tesamorelin delivers.

Tesamorelin is the only option. The COSMIC trials are Phase 3, double-blind, placebo-controlled studies published in peer-reviewed journals. No other GHRH analog has that level of evidence for visceral fat reduction. Sermorelin studies show metabolic benefits, but none demonstrate the 15–20% VAT reduction tesamorelin achieves. If your research grant or protocol requires published efficacy data for fat loss, tesamorelin is non-negotiable.

Use sermorelin. The bioidentical GHRH mechanism restores pulsatile GH secretion without overriding feedback loops, making it ideal for longevity research or GH deficiency models where metabolic intervention isn't the primary endpoint. Dosing is straightforward (300–500 mcg subcutaneous before sleep), cost is significantly lower, and receptor desensitization risk is minimal with proper cycling. Tesamorelin's fat-targeting effects and higher cost aren't justified unless visceral adiposity is part of the research question.

Use sermorelin. Studies show it increases slow-wave sleep duration by up to 23% in adults over 50, correlating with improved cognitive performance. Tesamorelin's sustained GH elevation doesn't target sleep architecture specifically. Its mechanism is optimised for lipolysis, not circadian rhythm modulation. Sermorelin's pulsatile GH release aligns with natural nocturnal GH secretion patterns, making it the validated choice for sleep research.

Tesamorelin is gaining traction here. Recent studies from Massachusetts General Hospital (2025) showed tesamorelin reduced liver fat by 18% in NAFLD patients over 24 weeks. Driven by the same visceral fat reduction mechanism. Metabolic syndrome research increasingly focuses on visceral adiposity as the primary driver of insulin resistance and cardiovascular risk. If your hypothesis centres on fat distribution rather than general GH dynamics, tesamorelin's specificity is an advantage.